Resumen
Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 455-458 |
Número de páginas | 4 |
Publicación | Canadian Journal of Neurological Sciences |
Volumen | 46 |
N.º | 4 |
DOI | |
Estado | Published - jul. 1 2019 |
Nota bibliográfica
Publisher Copyright:© 2019 The Canadian Journal of Neurological Sciences Inc.
ASJC Scopus Subject Areas
- Neurology
- Clinical Neurology
PubMed: MeSH publication types
- Journal Article